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Abstract 
The lifetime risk of a man getting diagnosed with prostate cancer is 1 in 6.  The diagnosis is 
made by the pathologist using staining methods and immunohistochemical markers to detect 
malignancy on tissue biopsy sections.  Quantitative phase imaging methods eliminate the need 
for stains and markers.  It exploits the intrinsic contrast from the refractive index differences in 
tissue.  The quantitative nature of this technique eliminates inter-observer variability.  QPI is 
sensitive to sub-nanometer level changes in tissue architecture.  Light scattering information is 
also accessible from QPI images since it records both the amplitude and the phase of light that 
passes through the sample.  In this thesis, I show the ability of QPI to distinguish between 
cancerous and benign samples.  I also show its ability to detect changes in stroma and nuclei 
through different stages of prostate cancer progression that are not detectable using conventional 
methods. 
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1. Introduction 
1.1 Overview 
Optically thin slices of tissue do not significantly scatter or absorb light.  Due to its transparent 
nature, in clinical pathology, contrast is extrinsically generated by adding dyes to make 
structures visible.  Tissue biopsy sections are traditionally stained with hematoxylin and eosin 
(H&E).  Hematoxylin stains nucleus in a deep blue-purple by a reaction that is not completely 
understood, whereas eosin non-specifically stains proteins pink and makes the cytoplasm and 
extra-cellular matrix visible[1].  When the pathologist suspects the presence of cancer on the 
H&E stained biopsy, a consecutive biopsy section is stained with specialized stains, 
immunohistochemical markers and/or molecular markers to make a final diagnosis.  These 
techniques can be expensive and time-consuming.   
Cells and tissue have intrinsic contrast in the form of refractive index differences between 
various structures.  In the 1930s, Zernike developed phase contrast microscopy in which the 
unscattered and scattered components of light are separated by a π/2 phase value, making 
transparent structures visible[2].  However, phase contrast images are qualitative.  Quantitative 
phase imaging (QPI) techniques image transparent structures and quantitate the change in the 
path length of light as it transmits through these structures.  In constant thickness samples such 
as tissue sections, the phase value is only dependent on the refractive index.  QPI techniques are 
sensitive to path length changes at the nanoscale level.   
In tissue, nanoscale fluctuations in path length correspond to changes in tissue architecture.  
Light scattering parameters can also be obtained from quantitative phase images.  This scattering 
information and quantitative phase information can be used in the diagnosis of disease.  In the 
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past, QPI has been used to diagnose prostate cancer in label-free tissue biopsies[3].  In this 
thesis, I describe the utility of QPI in studying optical changes in prostate tissue of varying 
severity of cancer.  
1.2 Outline 
In chapter 2, I elaborate on the interaction between light and tissue, and how information about 
light scattering through various structures can be retrieved from quantitative phase images. 
In chapter 3, I present the problems associated with prostate cancer diagnosis, more specifically, 
benign mimickers of prostate cancer and discuss the importance of prognostic tools. 
In chapter 4, I introduce gradient field microscopy (GFM) which is a quantitative tool that can 
help in separating prostate cancer from its benign mimickers by detection of the basal cell layer 
(myo-epithelial layer) that is absent in prostate cancer. 
In chapter 5, I discuss spatial light interference microscopy (SLIM), a quantitative phase imaging 
method and Fourier transform light scattering (FTLS), a tool to study tissue scattering.  I show 
some results on the utility of SLIM in detection of changes in stroma of prostate cancer of 
various Gleason grades and FTLS changes in nuclei of various stages of prostate disease. 
Finally, I summarize this thesis and discuss the future direction of this research. 
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2. Light-tissue interaction
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When light is propagated through tissue, there is a change in the irradiance, spectrum, 
polarization, phase, direction and coherence due to which information about tissue can be 
obtained [4-6].  The light-tissue interaction can be classified as elastic and inelastic.  Elastic light 
scattering occurs when the frequency of light is conserved.  This is different from dynamic light 
scattering where Doppler shifts caused by dynamic specimen such as live cells cause small 
changes in light frequency[7].  In diseases such as cancer, the morphological changes in tissue 
modify light properties such as scattering parameters and this can be used to diagnose disease.  
Tissue scattering basics are reviewed in this chapter in greater detail. 
While inelastic interactions such as emission and absorption are out of the scope of this thesis, 
spectral changes due to elastic scattering can hinder measurements based on inelastic interactions 
between light and tissue and is discussed in greater detail below[8]. 
2.1 Scattering window 
Biological tissue and cells is composed of various structures and organelles that have different 
refractive indices.  This difference in refractive index makes tissue highly scattering.  The optical 
microscope is a scattering instrument that makes measurement in real space (x,y,z)[9].   
The three major structures in cell are cell membrane, nucleus and cytoplasm.  The cell membrane 
encompasses the cytoplasm and is made of a phospholipid bilayer composed of proteins and 
glycoproteins that float on lipids.  The cytoplasm encompasses cytosol in which various 
                                                          
1
 The text in this chapter is adapted from: 
Kim, T., Sridharan, S., Popescu, G. Fourier transform light scattering of tissues in Coherent-domain optical 
methods, Second Edition, Edited by Tuchin, V.V., Springer (2012). 
Zhu, R., Sridharan, S., Tangella, K., Balla, A., Popescu, G. Correlation induced spectral changes in tissues. Optics 
Letters 36(21), 2011. 
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organelles such as mitochondria, golgi apparatus, endoplasmic reticulum, peroxisomes, 
lysosomes are suspended.  The cell nucleus is separated from the cytoplasm by the nuclear 
envelope and is the site of DNA replication and RNA translation[10]. 
The different cellular structures have different refractive indices due to varying compositions.  
This makes the cell a scattering medium.  Large structures such as nucleus scatter light at smaller 
angles whereas smaller organelles such as mitochondria scatter at large angles[11, 12].   
Light is absorbed by cells in accordance with the Beer-Lambert’s law which helps quantitate the 
decrease in intensity as light travels through material of thickness L: 
L
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Where ε is the extinction coefficient, ρ is the concentration of absorbing material and α is the 
absorption coefficient.  Since the human body is primarily composed of water, it is important to 
note that water does not absorb light significantly in the 200-1300nm spectral region as shown 
by studies by Hale and Querry [13].  Hemoglobin, a red blood cell protein that transports oxygen 
to tissue, is also a major contributor to the absorption spectrum[14].  Hemoglobin gets 
oxygenated by binding oxygen to iron atoms as red blood cells pass through the lungs and gets 
deoxygenated in tissue, changing its absorption spectrum.  Hemoglobin absorbs most in blue and 
green spectral regions.  
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Figure 1
2
: The graph for absorption coefficient vs. wavelength is shown for water, 
hemoglobin and deoxygenated hemoglobin.  From the absorption spectra, the tissue optical 
window can be obtained.  
In the 800-1300nm window, also referred to as the tissue optical window, the tissue exhibits low 
light absorption.  In this window, the scattering effect is dominant and absorption is an 
insignificant contributor.  This is the spectral region where tissue scattering experiments are 
performed. 
2.2 Scattering phase theorem 
Scattering phase theorem allows us to calculate the scattering mean free path ( sl ) and optical 
anisotropy (g) from the phase distribution in a tissue section of thickness L<< sl [15, 16].   
                                                          
2
 Figure adapted from Kim, T., Sridharan, S., Popescu, G. Fourier transform light scattering of tissues in Coherent-
domain optical methods, Second Edition, Edited by Tuchin, V.V., Springer (2012). 
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Figure 2
3
: (a): Light with amplitude U0 travels through tissue section of thickness L for 
which ls is the scattering mean free path.  (b): ko is the incident wave vector and ks is the 
scattered wave vector, q represents transfer of momentum, g is the optical anisotropy 
where g=cos θ  
The scattering mean free path ( sl  ) is defined from the Lambert-Beer’s law as the length over 
which the intensity of unscattered light drops to 1/e of its original value.  In tissue, this is the 
average step between two scattering events.   sl  is inversely proportional to the phase variance 
averaged over a certain tissue region as shown in equation[15] (1). 
r
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 (1) 
 Optical anisotropy is defined as the average cosine of the angle associated with a single 
scattering event.  It is the change in the direction of light propagation due to scattering.  g 
accounts for forward scattering and scales sl  to a higher value called transport mean free path ( tl
                                                          
3
 Figure adapted from Kim, T., Sridharan, S., Popescu, G. Fourier transform light scattering of tissues in Coherent-
domain optical methods, Second Edition, Edited by Tuchin, V.V., Springer (2012). 
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) where tl  = sl  /(1-g).  Optical anisotropy is related to both the phase gradient distribution and 
scattering mean free path in the region of interest as shown in equation[15] (2).  
2
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  (2) 
From the scattering phase theorem, it is evident that when the inhomogeneity in tissue is 
increased, the propagated light is scattered more which means the optical anisotropy value 
increases while the scattering mean free path reduces in length.   
2. 3 Correlation induced spectral changes in tissue 
Correlation induced spectral shifts or Wolf shifts refers to Wolf’s prediction that spatial 
correlations in a primary source affects the optical spectrum in the far zone[17].  These 
predictions were experimentally confirmed in acoustic waves, spectroscopic measurements on 
stellar objects and scattering media[18-21].  The frequency shift in spectral lines was explained 
by the medium scattering various wavelengths with differing strength which was dependent on 
the scattering angle[20].   
 
 
 
 
Figure 3
4
: A quantitative phase image of a prostate tissue microarray core of 4micron 
thickness with a region zoomed in. 
                                                          
4 Figure reprinted from Zhu, R., Sridharan, S., Tangella, K., Balla, A., Popescu, G. Correlation induced spectral 
changes in tissues. Optics Letters 36(21), 2011. 
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We measured this spatial correlation function on a quantitative phase image of an unstained 4µm 
thick prostate cancer tissue section which is shown in Fig. 3. 
We calculate the optical spectrum associated with scattering angle θ by starting with the 
Helmholtz equation:  
),()(),(),( 20
2
0
2  rUrkrUkrU   
Where k0 is the incident wave vector, χ is the dielectric susceptibility of optically thin specimen 
and the field is a function of the angular frequency ω and spatial coordinate r.  According to the 
Born approximation, the incident plane wave remains a plane wave inside the tissue.  By 
applying the Born approximation to (3) we get: 
zik
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Where zikeA 0)( is the incident plane wave.  We take the Fourier transform of the above equation 
with respect to r to obtain the field in wave vector form 
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The above equation expression is a variation of diffraction tomography in which the scattered 
field measured along the wave vector direction provides information about the spatial frequency 
component q=k-ki.   The scattering angle θ is related to the momentum transfer q by 
q=2k0sin(θ/2).  The susceptibility term is only dependent on kx and ky, so we define a new term 
2
1
22 )( yx kkk   and therefore )(
22
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 kkQ  and equation 3 becomes: 
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We obtain the scattered field in spherical terms by taking the 1D inverse Fourier transform with 
respect to kz 
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We ignore the term e
-iQz
/Q since it corresponds to the angular backscattering term.  We express 
this in terms of the power spectrum, which is the square of the amplitude term: 
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Where cosθ=Q/k0, k =k0sinθ and Si is the incident power spectrum.  This expression shows that 
the optical spectrum at distinct scattering angles is dependent on both the incident spectrum and 
the spatial power spectrum of the scattering tissue which is expressed as )(~2 k .  The distinct 
spatial frequencies of the medium can be viewed as a sinusoidal grating which diffracts longer 
wavelengths at larger angles.  The Wolf effect is the average result of this diffraction effect. 
We calculated the refractive index distribution n(x,y), the susceptibility χ(x,y) and power 
spectrum 
2
),(~ yx kk  from the quantitative phase image of the 4µm thick tissue section shown in 
fig 1.  The sample was imaged with white light of a Gaussian spectrum centered at 4x10
15
 rad/s 
and a standard deviation 1x10
14
 rad/s.  We used equation 7 to calculate the spectrum of scattered 
light. 
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Figure 4
5
: (a): Spectrum Vs Angle for scattered light from the tissue in Fig 1 (b): The 
relative change of mean frequency; negative values correspond to a shift in the red light 
spectrum.  
When we closely examine the scattered spectrum at each angle, we notice that there is a 
modification from the original spectrum with red spectral shifting (Fig 3a).  This is consistent 
with static scattering.  We quantified the overall shift by defining 000 /)'()(   where ω’ 
is the shift in mean frequency and ω0 is the original mean frequency.  The red shifts are 
significant (Fig 3b).  The maximum shift in red is more than 10%.  By plotting the spectrum in 
absence of correlations, we see that the normalized spectrum at different angles does not change 
(Fig 3b inset).  This proves that the shift is entirely due to spatial correlations. 
Our study shows that the measured scattering spectrum at various angles is affected by tissue 
spatial correlations.  These spatial correlations change the shape of the emitted field without 
affecting the emission process.  This effect can cause errors in spectroscopic measurements of 
tissue due to the significant effect in angular and spectral resolved measurements.  This can be 
resolved by simultaneous measurement of morphology and spectroscopy.  
                                                          
5
 Figure reprinted from Zhu, R., Sridharan, S., Tangella, K., Balla, A., Popescu, G. Correlation induced spectral 
changes in tissues. Optics Letters 36(21), 2011. 
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3. Prostate Cancer 
The prostate is an exocrine gland weighing 30-40g in the adult male reproductive system that is 
located at the base of the urinary bladder.  The urethra and the ejaculatory duct pass through the 
prostate gland.  The prostate secretes 12% of the ejaculatory fluid into the duct which opens into 
the prostatic urethra [22].  In 1968, McNeal performed serial sectioning of the prostate gland to 
study the various structures within the prostate.  The gland can be divided into four zones.  The 
central zone comprises approximately 25% of the gland and surrounds the ejaculatory duct.  It 
consists of large acini with irregular contours that project into the lumen of the gland; the 
epithelium comprises big nuclei in a crowded arrangement with granular cytoplasm [23, 24].  
The peripheral zone, which comprises 70% of the prostate, surrounds the distal region of the 
urethra and has small acini with smooth walls; the epithelium has pale cytoplasm with small 
basal nuclei [24].  Most cases of prostate cancer arise within the peripheral zone of the prostate 
gland [25].  The third zone is the transition zone which comprises 5% of the prostate and 
surrounds the proximal portion of the urethra; the epithelium is histologically similar to the 
peripheral zone [24].  Most cases of benign prostatic hyperplasia arise in the peripheral zone of 
the prostate gland [26].  The fourth zone of the prostate is the anterior fibromuscular stroma, 
which is a non-glandular region anterior to the prostate gland [23]. 
The acini of the prostate open into prostatic ducts which in turn secrete into the prostatic urethra.  
The acinar cells primarily are made of columnar epithelium, neuroendocrine cells and basal cells 
[22, 27].  The columnar epithelial cells are 10-12µm in size and secrete prostate specific antigen 
(PSA) and prostatic acid phosphatase (PAP); it also requires androgen for maintenance [23].  
Neuroendocrine cells are scattered throughout the acini and basal cells rest on the basement 
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membrane [23].  Prostatic stroma is a collection of various cell types, such as fibroblasts, smooth 
muscle cells, blood, lymphatic vessels and autonomic nerve fibers [28]. 
The most common initial symptom of prostate disorder is urinary difficulty, since the urethra 
passes through the prostate gland.  A person might get a needle biopsy to check for prostate 
cancer if their serum PSA reading is above the normal cut-off of 4.0ng/L or suspicion during a 
digital rectal exam (DRE).  The needle biopsy specimen is embedded in paraffin and sliced using 
a microtome.  The tissue slice is then placed on a glass slide and stained with hematoxylin and 
eosin (H&E) stain.  The pathologist examines the H&E stained biopsy for the presence of the 
basal or myo-epithelial layer to exclude the diagnosis of prostate cancer.  The basal cell 
membrane is breached in prostate cancer and cancerous epithelium invades the surrounding 
stromal region.  Conditions such as high-grade prostatic intra-epithelial neoplasia, which is a 
benign mimicker of prostate cancer, can make the diagnosis difficult.  In the following section, I 
discuss benign prostate conditions and prostate cancer in more detail. 
3.1 Benign Prostate Conditions 
The two benign prostate conditions that were studied using QPI are benign prostatic hyperplasia 
(BPH) which commonly affects older men and is often characterized by an enlarged prostate and 
high grade prostatic intra-epithelial neoplasia (HGPIN) which is a benign mimicker of prostate 
cancer. 
3.1.1 Benign Prostatic Hyperplasia (BPH) 
Approximately 50% of all men over the age of 40 will develop benign prostatic hyperplasia 
(BPH) [29].  BPH is a condition in which the number of epithelial and stromal cells in the 
prostate is increased.  The increased cell count could be due to increased epithelial or stromal 
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proliferation or decreased rate of apoptosis [30].  BPH is diagnosed on a trans-urethral resection 
of the prostate (TURP) samples.  A diagnosis of BPH cannot be made on a needle biopsy sample 
since the transition zone is not sampled in most needle biopsies.  In our study of prostate 
conditions, we used tissue from individuals with BPH as control since it’s a common condition 
afflicting individuals in the age-group primarily affected by prostate cancer. 
3.1.2 High-grade prostatic intra-epithelial neoplasia (HGPIN) 
High-grade prostatic intraepithelial neoplasia (HGPIN) is a benign condition that is considered to 
be a precursor to prostate cancer [25, 31, 32].  HGPIN is observed in 0 to 24.6% of prostate 
needle biopsies with mean reported incidence of 7.6% [33, 34].  Prominent nucleoli and presence 
of Roman bridges are common hallmarks of high-grade PIN [33, 34].  HGPIN is not very 
common in the transition zone, has evenly spaced glands with focal to no necrosis and patchy 
basal cell layer distinguishing it from prostate adenocarcinoma [33, 34].  Detection of 
myoepithelial cells or basal cells by usage of antibody against cytokeratin 34BE12 and/or p63 
marker is performed by the pathologist to exclude the diagnosis of carcinoma in suspected cases 
of HGPIN [34].  The diagnosis of HGPIN is often made in patients suspected of having prostate 
cancer and usage of special stains can delay diagnosis causing anxiety to patients.  In our lab, we 
developed a qualitative imaging technique, Gradient Field Microscopy (GFM) that detects the 
basal cell layer in real-time preventing the delays caused by immunostains.  GFM is described in 
detail in the next chapter. 
3.2 Prostate Cancer 
Cancer statistics from 2010 indicate that prostate cancer is the most commonly diagnosed cancer 
among men (not including skin cancer) in the United States of America and the second leading 
cause of cancer-related deaths[35].  The SEER program by National Cancer Institute estimates 
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that there will be 241,740 new cases of prostate cancer and 28,170 men will die of prostate 
cancer in the United States in 2012[36].  Due to the high fatality rate and economic costs related 
to prostate cancer care, there was a need for an early detection tool for prostate cancer. 
A good screening tool will diagnose a condition in its early stages and the number of people 
diagnosed with the condition through screening will stabilize to the pre-screening numbers after 
an initial spike.   The prostate specific antigen test (PSA) was developed to detect early prostate 
cancer and needle biopsies were performed in individuals with serum PSA above 4.0 ng/L.  PSA 
screening increased the number of people diagnosed with prostate cancer and the numbers did 
not go down to the pre-screening era levels [37]. 
 
Figure 5
6
: PSA screening was introduced in 1986.  Panel A shows that while the spike 
associated with screening reduced, it did not stabilize to pre-screening levels.  Panel B 
shows the increasing trend in the ratio of prostate cancer incidence relative to 1986 when 
screening was first introduced.  
                                                          
6
 Figure reprinted from Welch, H.G. and P.C. Albertsen, Prostate cancer diagnosis and treatment after the 
introduction of prostate-specific antigen screening: 1986-2005. Journal of the National Cancer Institute, 2009. 
101(19): p. 1325-9. 
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The median age of diagnosis of prostate cancer is 67 years while the median age of death due to 
prostate cancer is 80 years with 71% of death due to disease occurring at age above 75 years 
[36].  Hence, in 2008, the United States Preventive Services Task Force recommended against 
PSA screening for men over the age of 75 years [38].  Further studies showed that while the life-
time risk for prostate cancer diagnosis is 15.9%, the risk of dying of the disease is 2.8% and that 
1.2 million new cases of prostate cancer would be diagnosed if all American men between the 
ages of 62 and 75 years underwent prostate biopsy [39].  Studies have shown that 1/3
rd
 of all men 
in the age group of 40-60 years and 3/4
th
 of all men above the age of 75 years have histologic 
prostate cancer [40, 41].  Out of every 1000 men who undergo surgery to treat prostate cancer, 
10-70 men suffer serious complications; 200-300 men have undesirable long-term effects such as 
bowel dysfunction, urinary incontinence and erectile dysfunction[42].  Based on these findings, 
the USPSTF recommended against PSA screening for men of all ages in 2012 [39]. 
Current data and research indicate that prostate cancer is over-diagnosed.  Among men affected 
by the disease, some have asymptomatic slow growing tumors while others have a more 
aggressive form of the disease which requires early and aggressive intervention.  Hence there is a 
need for prognostic tools in prostate cancer such as Gleason grading. 
3.2.1 Gleason Grading of Prostate Cancer 
The Gleason grade is the most widely used grading scheme in prostate cancer.  The system was 
developed by Dr. Donald Gleason in the 1960s and is based on glandular differentiation seen in 
hematoxylin and eosin (H&E) stained slides [43, 44].  The Gleason score has been proven to be 
an indicator of tumor size, metastasis, treatment and outcome [44-47].  
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The variation in grades on a scale from 1-5, in order of increasing severity, is based on glandular 
differentiation and glandular presence in stroma [43, 44, 48, 49].  The primary grade is the 
pattern present in maximum biopsy area and the secondary grade is the second most prominent 
pattern.  The secondary area has to encompass atleast 3% of total biopsy area [50].  The two 
grades are added to provide a Gleason score of 1-10.  More recently, tertiary patterns are 
reported (area <5%) on the pathology report if it is of Grade 4 or 5 due to possible presence of 
metastasis [51]. 
 
Figure 6
7
: Standard drawing of Gleason grading system made by Dr. Donald F. Gleason  
                                                          
7
 Figure reprinted from Gleason, D.F., Classification of prostatic carcinomas. Cancer Chemother Rep, 1966. 50(3): p. 
125-8 
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A modified Gleason grading system was adopted in 2005 at the United States and Canadian 
Academy of Pathology meeting [52].  Gleason grading is done at 4X or 10X magnification with 
confirmation at 20X or 40X to detect fusion of glands and necrosis.   
In current clinical practice, cancer of Gleason grade 1 is rarely diagnosed.  It is suspected that 
immunostains would re-label the cases categorized by Dr. Gleason as Grade 1 would be re-
categorized as adenosis and some cases of cribriform grade 3 adenocarcinoma as high-grade 
prostatic intra-epithelial neoplasia (HGPIN) [33, 53].   
Gleason grade 2 consists of irregular glands that are smaller than normal, but larger than other 
cancerous glands and the tumor is well circumscribed.  The cribriform pattern described by Dr. 
Donald Gleason is no longer considered Gleason grade 2 [33, 52].  Gleason grade 2 is rarely 
diagnosed due to poor reproducibility among pathologists and poor correlation on radical 
prostatectomy specimen [33].  The diagnosis of Gleason score 2-4 (grades 1,2) has decreased 
from 24% in 1991 to 2.4% in 2001 [54]. 
Gleason grade 3 glands are medium to small size, singular with infiltrating edges [44].  The 
cribriform (gland within gland pattern) is also observed in Gleason grade 3, however, they do not 
have necrosis [44].  Cribriform Gleason grade 3 glands resemble HGPIN glands with the absence 
of basal cell layer, reduced spacing between glands and possible perineural invasion or extra-
prostatic extension [33].  Singular cells as described by Dr. Gleason are no longer considered 
grade 3 [52]. 
Gleason grade 4 consists of small glands that are fusing into one another and cribriform patterns 
with irregular edges as opposed to the smooth edges seen in cribriform glands of Gleason grade 3 
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[33].  Gleason grade 4 also has a hypernephromatoid subtype which has similar glandular pattern 
as other grade 4 glands but has cleared cytoplasm resembling renal cells [43].   
Gleason grade 5 comprises of sheets or cords of cells with no glandular differentiation [43].  A 
cribriform pattern that looks like Gleason grade 4 with central region displaying necrosis, termed 
comedonecrosis is also considered Gleason grade 5 pattern [44]. 
Gleason scores are often grouped together as score 2-4: well-differentiated; score 5-6: 
moderately differentiated; score 7: moderately to poorly differentiated and 8-10: poorly 
differentiated [33].  There have been studies that have shown that Gleason score 7 is a 
heterogeneous disease with differential outcomes for Gleason grade 4+3 as opposed to Gleason 
grade 3+4 [33, 55].  However, there are also studies disputing this finding [56-58].  The reasons 
for this disagreement in results could be the inter-observer differences reported in Gleason 
grading or the difference between the grades seen in needle biopsy and prostatectomy specimen 
[59-61]. 
In this thesis, I studied differences in the stroma adjoining the gland of Gleason grade 3 and 
Gleason grade 4 glands to explore the possibility of Gleason score 7 being a heterogeneous 
disease.  I also studied the difference in nuclear scattering in prostate tissue of varying levels of 
glandular differentiation.  This is explained in detail in Chapter 5.     
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4. Qualitative Diagnosis Methods
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The distinction between cancer and normal biopsies is made by the detection of basal cell layer.  
Gradient field microscopy (GFM) is a high contrast method that detects these basal cells.  GFM 
also has the advantage of high acquisition speed.  Since the contrast is increased optically, there 
is no need of post-image processing.  Thus, GFM naturally provides an ability to image in real-
time and the acquisition speed is limited only by the acquisition speed of the detector used in the 
setup. 
4.1 Gradient Field Microscopy (GFM) 
Figure 1 shows the setup for gradient field microscopy (GFM), which is an experimental setup 
for the Fourier filtering using a sinusoidal amplitude mask.  GFM is built as an additional 
module to a commercial bright field microscope, which is composed of the components from the 
condenser lens to the tube lens.  The aperture stop closed down to the minimum size in order to 
obtain high spatial coherence in the white light illumination.  From the image plane of the 
microscope, there is a relay of optical components comprising two lenses to form a 4f system and 
a spatial light modulator (SLM).  The first Fourier lens, L1, with the focal distance f1=75mm is at 
f1 away from the image plane, and the SLM is located at f1 away from L1 which is the Fourier 
plane of the image plane of the microscope.  The second Fourier lens is at its focal distance, 
f2=150mm, away from the SLM and forms the modulated image at f2 away from itself, where the 
                                                          
8
 The text in this chapter is reprinted with permission from: 
Kim, T., Sridharan, S., Popescu, G. Gradient field microscopy of unstained specimens, Optics Express 20(6), 2012. 
Kim, T., Sridharan, S., Popescu, G., Gradient field microscopy allows label-free disease diagnosis (invited), Laser 
Focus World, 48 (8), (2012) 
Kim, T., Sridharan, S., Kajdacsy-Balla, A., Tangella, K., Popescu,G.,, Gradient field microscopy for label-free 
diagnosis of human biopsies, Appl. Opt. (Special Issue on Holography), 52 (1), A92-A96 (2013) 
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detector (Andor iXon
+
 EMCCD) is located.  As a whole, GFM module increases the contrast by 
imaging the first-order derivative of the phase of the sample as well as the magnification 
determined by the ratio between the two Fourier lenses, which is 2 in our setup. 
The SLM in our setup is a liquid crystal panel taken from Epson Powerlite S5 commercial 
projector sandwiched between two cross polarizers.  The top inset of figure 1 is projected to the 
amplitude SLM and the bottom is the profile of the sinusoidal modulation taken along the dashed 
line.  The contrast ratio of this device, 400/1, provides enough attenuation at where the projected 
value on the liquid crystal is zero.  Furthermore, the sine modulation period is calculated to be 
7.8mm (13μm/pixel, 600pixels/period) and it yields the shift of 2λf/a=20µm between the two 
separated beams and the DC field locates at the middle of the two beams. 
 
Figure 7
9
: GFM Set-up.  The inset shows the modulation filter projected on SLM for sine-
GFM (top) and linear-GFM (bottom).  
                                                          
9
 Figure reprinted from Kim, T., Sridharan, S., Popescu, G. Gradient field microscopy of unstained specimens, 
Optics Express 20(6), 2012 
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4.2 HGPIN Diagnosis using GFM 
As mentioned earlier, HGPIN is a benign condition in which biopsy samples have morphological 
features associated with prostate cancer.  The only distinguishing characteristic is the presence of 
the myoepithelial cell layer in HGPIN biopsies, but not in the cancer biopsies.  The 
myoepithelial cell layer is patchy and is detected with immunohistochemical markers which can 
delay diagnosis by a day or longer.  Due to their small size, there is a sharp change in optical 
path length at the stroma-epithelium boundary making them clearly visible in GFM images. 
We imaged HGPIN samples using the 100X/1.4NA oil immersion objective on the GFM setup.  
We had to use the mosaic feature and stitched 154 images to obtain the final GFM image.  By 
qualitative examination of the boundary of the stroma and epithelium, we were able to detect the 
basal cells in the GFM images of cores with HGPIN.  These results are shown in the figure 
below.   
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Figure 8
10
: Left shows a prostate tissue microarray core with HGPIN imaged with GFM.  
Due to its high contrast, edges are prominent.  The figures on the right show areas from 
prostate TMA zoomed in with the basal cell layer highlighted.  
  
                                                          
10
 Figure reprinted from Kim, T., Sridharan, S., Popescu, G. Gradient field microscopy of unstained specimens, 
Optics Express 20(6), 2012. 
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5. Quantitative Diagnosis 
Zernike developed the Nobel-prize winning technique, phase contrast microscopy, in the 1930s.  
In a phase contrast microscope, the sample is illuminated by spatially coherent white light.  The 
component of light that passes through cellular structures is retarded in phase, and by adding an 
additional π/2 delay to this scattered component, the path-length difference between the scattered 
and unscattered components of light increases to λ/2 making transparent objects visible[62].  In 
the 1940s, Gabor developed holography which enabled the recording of both the amplitude and 
phase information[63]. 
Spatial light interference microscopy (SLIM) was developed in the Quantitative Light Imaging 
(QLI) group at University of Illinois by combining principles from Zernike’s phase contrast 
microscopy and Gabor’s holography as a quantitative phase imaging method that is sensitive to 
path-length changes of upto 0.3nm spatially and 0.03nm temporally[64]. 
5.1 Spatial Light Interference Microscopy (SLIM) 
 
Figure 9: SLIM is an add-on module to a commercial phase contrast microscope.  
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Spatial light interference microscopy (SLIM) is a quantitative phase imaging method that is 
described in detail in [64].  Briefly, SLIM is an add-on module to the commercial phase contrast 
microscope (Zeiss Axio Observer Z1) and adds 3 additional phase shifts in increments of π/2 to 
the un-scattered component of light passing through the sample.  The SLIM module projects the 
back focal plane of the objective to the liquid crystal phase modulator which introduces the 
additional phase shifts.  We record 4 intensity images and calculate a quantitative phase map 
from these images.  The final image is calculated by the formula:  
   
 ,
0
0
2
, , ,
h x y
x y n x y z n dz


       (54) 
Each term in this equation is defined as follows. 
λ: Central wavelength of light. In SLIM, light used is white light, so it corresponds to 552.3nm, 
h(x,y): Local thickness fluctuations n(x,y,z): Local refractive index fluctuations, n0: Refractive 
index of surrounding medium. 
SLIM measures optical path length changes with a sensitivity of 0.3nm spatially which 
corresponds to dry mass sensitivity of 1.5fg/μm2[65].  In the past, our group demonstrated that 
refractive index could be used as a marker to differentiate cancer and normal areas of the prostate 
as well as to measure cell growth and dynamics[65-68].   
5.2 Fourier Transform Light Scattering (FTLS) 
QPI techniques such as SLIM record both the amplitude and the phase of the field at the image 
plane.  Since complete information about the field is available, the field distribution at all other 
planes can be calculated.  The image and scattering field have a Fourier transform relationship.  
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Fourier transform light scattering (FTLS) is a sensitive method to study angular scattering 
information since the field is measured at the highly uniform image plane [69, 70]. 
We used SLIM and FTLS to quantitatively study changes in prostate nuclei and stroma through 
various pathological stages. 
5.3 Optical changes in prostate stroma 
5.3.1 Motivation 
The Gleason grading system focuses primarily on changes in the glandular structure and 
therefore the epithelium.  The immunostains used in prostate pathology, such as high molecular 
weight cytokeratin, p63 and AMACR focus on various aspects of the epithelium.  More recently, 
some molecular studies have focused on the stroma in prostate cancer. 
The stroma is a complex environment consisting of the extracellular matrix, fibroblasts, smooth 
muscle cells, growth factors, regulatory receptors, blood vessels, nerve fibers and immune cells 
[28].  In the prostate, the primary stromal components are fibroblasts and smooth muscle cells 
[71].  The various components of the stroma provide adhesion, growth factor secretion and 
regulation, structural framework and support, cell attachment and migration and permeability 
[72, 73].  In response to carcinoma in the epithelium, the repair mechanism in stroma is activated 
[74].  The stromal changes seen in cancer using immunohistochemistry or molecular studies 
mimic the changes seen in wound healing mechanisms such as increased growth factor secretion, 
angiogenesis, matrix remodeling, elevated immune response and increased protease activity [75-
79].  These changes also include a switch to the activated myofibroblast phenotype from 
fibroblast characterized by increased secretion of vimentin and smooth muscle to myofibroblast 
with reduced levels of α-smooth muscle actin and calponin [74, 77, 78, 80, 81].   
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We used refractive index as an intrinsic marker to study changes that occur in stroma due to 
prostate adenocarcinoma of various Gleason grades.  In SLIM images, individual strands of 
stroma are clearly visible.  We focused on the layer of stroma immediately adjoining the gland 
since we hypothesized that the progression of disease should first affect this layer as 
adenocarcinoma involves epithelial proliferation into the stroma.  Our results showed that the 
variation in the stromal architecture increases with increasing Gleason grade.  Since SLIM is 
sensitive to nanoscale fluctuations in tissue morphology, we believe that the variation we see is 
indicative of protein expression and distribution changes in various stages of prostate disease. 
5.3.2 Materials and Methods 
We obtained tissue microarray slides from the TMA2 set of the Co-operative Prostate Cancer 
Tissue Resource (CPCTR) database at the University of Illinois at Chicago- College of 
Medicine.  TMA2 is a set of 4 slides that contain approximately 1200 cores of Gleason scores 4-
10 that are well characterized and graded by consensus among multiple pathologists.    
We imaged unstained slides with tissue thickness of 4µm using SLIM.  The slides were imaged 
using the 10X/0.3NA objective and the mosaic feature on the Zeiss microscope for each block 
comprising of 20 cores.  The mosaic feature can be adjusted to set up multiple focus planes, 
ensuring that all sample areas are in focus.  Imaging time for 20 cores with the inclusion of 
manual work such as setting up the mosaic and focus points is 40 minutes.  The images were 
stitched together using an ImageJ plugin built in-house and individual cores were cropped out to 
the size of 3000x3000pixels which is approximately 9 frames stitched together. 
After the completion of label-free imaging using SLIM, the same slides were sent to Provena 
Hospital for H&E staining.  These slides were then digitized using the Nanozoomer at the 
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Institute of Genomic Biology, University of Illinois at Urbana-Champaign.  Using the 
information from the CPCTR database, we identified cores with Gleason grade 3 cancer from a 
final score of 6 and Gleason grade 4 cancer from a final score of 8 (4+4), 7 (4+3) and 9 (4+5).  
Occasionally, the final Gleason grade diagnosed on the patient and the Gleason grade observed 
on the tissue sample we obtained are not the same.  To eliminate errors due to sampling, our 
collaborating pathologists confirmed the presence of grade 3 and grade 4 glands in the cores we 
used for our analysis.   
We then segmented individual strands of stroma on the SLIM images on the pathologist-
identified glands of a specific grade using ImageJ and a Wacom tablet with the H&E image as a 
reference for both grade 3 and grade 4.  One advantage we had with the SLIM images over H&E 
stained images is the clear visibility of individual stromal strands between glands, including 
fusing glands.  We calculated the magnitude and standard deviation of the phase and the 
magnitude of the gradient of the phase in these stromal regions of interest (ROI) using another 
plugin built in-house combined with the measurement features on ImageJ.  With these 
measurements we were able to calculate the ratio of the phase gradient to the square of the 
variance, which is related to g (anisotropy factor), the average cosine of the scattering angle 
associated with a single scattering event [15, 16]. 
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Figure 10: SLIM image with the corresponding H&E image of a tissue microarray (TMA) 
core of prostate with Gleason score 6 (3+3) adenocarcinoma.  On the H&E, pink areas are 
stroma and the purple areas are nuclei, epithelium.  On SLIM, we can clearly see 
individual strands of stroma even at 10X/0.3NA.  The SLIM image is 3000x3000pixels and 
is approximately 10 images stitched together from the mosaic imaging set up on Zeiss.  
Also, an individual strand of stroma surround the gland has been marked for 4 glands on 
the SLIM image.  
5.3.3 Results 
55 cores with Gleason grade 3 cancer and 55 cores with grade 4 cancer were used for analysis.  
A single layer of stroma adjoining the gland was segmented to generate 118 ROIs for grade 3 
and 117 ROIs for grade 4.  We found significant differences in the square of the ratio of phase 
gradient to phase variance (anisotropy factor analog) as shown in Fig. 4, 5.  Using the non-
parametric Mann-Whitney test, the values for anisotropy-analog were determined to be higher 
for grade 4 (p=3.76E-6).  Also, the value for the magnitude of the phase gradient was higher in 
cases with grade 4 cancer than grade 3 (p=7. 5E-5) (results not shown). 
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Figure 11: The distribution of anisotropy values is over a wider range for the stroma 
surrounding grade 4 glands and the difference between the two groups is significant.  
We further analyzed Gleason grade 4 stroma since the value of the anisotropy parameter was 
distributed over a wide range of values.  We compared anisotropy values in the grade 4 stroma 
among 15 patients (34 ROIs) with final diagnosis of Gleason score 8 (4+4) and 16 patients (42 
ROIs) with final diagnosis Gleason score 9 (4+5) as shown in Fig. 6.  Our analysis showed that 
the level of disorganization is higher in patients with Gleason score 9 (Mann-Whitney, p=5.91E-
5).   
 
Figure 12: The distribution of anisotropy values is over a wider range for the stroma 
surrounding grade 4 glands from patients with a final diagnosis of Gleason score 9 (4+5) 
adenocarcinoma than that of Gleason score 8 (4+4) adenocarcinoma.  The difference 
between the two groups is significant.  
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5.3.4 Discussion 
We calculated the square of the ratio of the phase gradient to phase variance, which is the 
variable term in the calculation of the anisotropy factor (g).  This substitution was made since an 
anisotropy calculation over a small area of stroma which the number of scattering angles 
measured.  This in turn, pushes g to higher cosine values.  Anisotropy is directly related to the 
optical roughness of the tissue.  We can see that the anisotropy is higher for the stroma adjoining 
glands of grade 4 cancer and the distribution is over a very wide range, whereas for grade 3, the 
value is small and distributed over a narrow range.  These results also translate over when we 
compare grade 4 regions among patients with final diagnosis of Gleason score 8 and 9.  In 
immunohistochemistry studies performed by other groups, hyaluronan (HA) level was observed 
to be high in the stroma of prostate biopsies of higher Gleason grades but HA receptor CD 44 
level is inversely related to Gleason grade [82].  High platelet-dervived growth factor (PDGFR-
β) expression and low expression of whey acidic protein family member WFDC1/PS20 has also 
been seen in stroma adjoining high Gleason grade glands [83, 84].  In another study, an increased 
level of stromal cells with fibroblast and myo-fibroblast phenotype and reduced levels of smooth 
muscle actin cells were observed in proliferative cancerous tissue of prostate [85].  In-vitro 
studies have shown the ability of prostate fibroblasts to transform into myo-fibroblast cells [86, 
87].  While the label-free nature of SLIM prevents us from knowing the exact molecular or 
morphological change that leads to the increased diversity we see in the anisotropy measurement,  
all the changes documented with immunohistochemistry would contribute to increased 
disorganization in the stroma which we measure as optical anisotropy.  One advantage of SLIM 
is that we can measure the final effect of all the molecular changes which cannot be done in 
immunohistochemistry due to its inherent reactive nature.   
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In grade 4 adenocarcinoma, we see that there is a wide distribution range of anisotropy values.  
This could be due to increased invasiveness seen in some Gleason grade 4 cancers [55].  The 
importance of stromal changes in cancer outcomes and invasiveness has been demonstrated in 
the breast and colon in the past [78, 88-91] and a preliminary study done in our lab shows that 
the stroma adjoining glands is indicative of tumor aggressiveness.  
The importance of stromal regulation of prostatic epithelium has been demonstrated in in-vitro 
studies in the past.  Prostate epithelium cultured on reconstituted extra-cellular matrix showed 
increased levels of prostate specific antigen and prostatic acid phosphatase as opposed to 
increased cell growth and reduced PSA, PAP levels seen in cells grown on plastic plates [92].  In 
our study, we saw changes in the single layer of stroma adjoining glandular epithelium. This 
might be indicative of stroma-epithelial cross-talk previously seen in literature.   
Our results are significant since this is the first time, to our knowledge, that differences were 
seen in stroma in label-free images of prostate cancer cores of various Gleason grades.  Further 
studies need to be done to explore the prognostic significance of the stromal diversity seen in 
various Gleason grades.  Also, with the addition of new parameters, we might be able to 
quantitatively differentiate between Gleason grade 3 and 4 adenocarcinoma proving to be a 
valuable tool for pathologists. 
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5.4 Optical changes in prostate nuclei
11
 
5.4.1 Motivation 
In clinical practice, the nuclear aspects that are of interest to pathologists are nuclear size and 
shape, mitotic count, nucleolar count and chromatin changes.  In a wide range of cancers, 
lobulation of nuclei, asymmetric arrangement of heterochromatin aggregates, irregular folds in 
nuclear membrane, enlarged nucleoli and cell-to-cell variation in number of nucleoli are 
hallmarks of cancer [93].  While prostate cancer and PIN (prostatic intra-epithelial neoplasia) is 
characterized by increased nucleolar count and prominently basal nucleoli, nuclear properties are 
not a part of the Gleason grading system.   
We used quantitative phase imaging methods to study changes in nuclei in unstained tissue 
increasing Gleason grades.  We characterized changes in the dry mass, dry mass density and area 
of the nucleus from quantitative phase images obtained from SLIM.  We also studied the spatial 
organization of the nucleus by studying the spatial scattering of light passing through the nuclei.  
Our results show that there is a change in nuclear dry mass of cancerous and normal tissue; and 
spatial scattering spectrum can be used to separate tissue of varying Gleason grades.   
5.4.2 Materials and Methods 
We obtained tissue microarray (TMA) set from the Cooperative Prostate Cancer Tissue Resource 
(CPCTR) database.  For our analysis, we had 2 patients with benign prostatic hyperplasia (BPH), 
1 patient with Gleason score 4 (2+2) adenocarcinoma, 1 patient with Gleason score 6 (3+3) 
adenocarcinoma, 1 patient with Gleason score 7 (4+3) adenocarcinoma and 1 patient with 
Gleason score 8 (4+4) adenocarcinoma.  They were grouped into three groups for analysis 
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 The text in this section is adapted from: 
Sridharan, S., Pham, H., Wickland, D., Tangella, K., Macias, V., Kajdacsy-Balla,A., Popescu, G., FTLS of nucleus 
during prostate cancer progression (manuscript in preparation)  
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purposes: “BPH” with 2 patients with benign prostatic hyperplasia, “low-grade tumor” with the 
patients with Gleason scores 4 and 6 and “high-grade tumors” with the patients with Gleason 
scores 7 and 8.  Each core had 150-800 nuclei that were used in our analysis.  We used benign 
prostatic hyperplasia (BPH) tissue as control due to its high incidence in the demographic 
affected by prostate cancer.  BPH affects 50-60% of men in their 60s and 80-90% of men in their 
70s; and the median age for patients with prostate cancer is 67 years [38, 94].  While Gleason 
score 7 is usually considered intermediate risk, we categorized our patient as high-grade cancer 
since his Gleason score was 4+3 which is associated with worse prognosis that 3+4 [55].  
The unstained tissue microarray slides were imaged using the 40X/0.75NA objective in SLIM.  
The mosaic feature on Zeiss was used to image each core which was approximately 100 frames.  
The mosaic feature can be adjusted to set up multiple focus planes, ensuring that all sample areas 
are in focus.  The images were stitched together using an ImageJ plugin built in-house and 
individual cores were cropped out to the size of 10000x10000 pixels which is approximately 100 
frames stitched together (Fig 13.1). 
The images were segmented using a Wacom tablet, ImageJ and plug-in built in our lab.  
Individual nuclei were isolated as regions of interest (ROI) manually using a Wacom tablet.  Our 
in-house plugin crops and pastes the phase images of the isolated nuclei in a zero-phase 
background image in their original positions (Fig 13.3).  This allows us to study the spatial light 
scattering of the nuclei.   
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Figure 13
12
: Top Left: 40X SLIM image of prostate TMA core with Gleason score 4 (2+2) 
adenocarcinoma with the highlighted area zoomed in on Top Right image.  Bottom Left: 
Isolated Nuclei from the image on Top Left, with the highlighted area zoomed in on Bottom 
Right image.  
5.4.3 Results 
5.4.3.1 Nuclear Dry Mass Density, Area of Nucleus and Nuclear Dry Mass 
In order to study the nuclear changes that occur in prostate cancer we studied the distribution of 
nuclear area, nuclear density and the dry mass of nucleus.  The nuclear area was calculated by 
manually segmenting the nucleus and using ImageJ to measure the area of each nucleus.  We 
found that the area of the nucleus increases in higher grade nuclei (Gleason score 7 and 8) when 
compared to that of benign prostatic hyperplasia patients (t-test, p=2.42E-10).  However, the 
nuclear area of low-grade cancer is comparable to that of BPH while significantly lower than 
high-grade cancer nuclei (t-test, p=1.19E-79).  We compared the nuclear density which is related 
to phase value by the following relation: 
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 Figure reprinted from Sridharan, S., Pham, H., Wickland, D., Tangella, K., Macias, V., Kajdacsy-Balla,A., 
Popescu, G., FTLS of nucleus during prostate cancer progression (manuscript in preparation)  
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where φ is the phase value measured by SLIM in radians and γ =0.2ml/g is the refractive 
increment.  We found that the nuclear density is increased in lower grade cancer (Gleason score 
4, 6) when compared with BPH nuclei (t-test, p=1.6E-57).  In higher grade cancer, the nuclear 
density is comparable to that of BPH nuclei but significantly different from that of lower grade 
cancer (t-test, p=1.82E-50).   
 
Figure 14
13
: Left: Illustrates the differences in the distribution of nuclear area among 
prostate cancer cores of various grades Right: Illustrates the differences in the distribution 
of nuclear dry mass densities among the various progression groups.  
Nuclear dry mass in all grades of prostate  cancer is higher than that of BPH due to the increased 
mass density in lower grade cancer and higher nuclear area in high grade cancers (t-test, 
p=2.13E-25). 
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 Figure reprinted from Sridharan, S., Pham, H., Wickland, D., Tangella, K., Macias, V., Kajdacsy-Balla,A., 
Popescu, G., FTLS of nucleus during prostate cancer progression (manuscript in preparation)  
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Figure 15
14
: The nuclear dry mass is comparable among all the cancer groups but is 
significantly greater than the control (BPH) group nuclear dry mass. 
5.4.3.2 FTLS Study of Prostate Cancer Progression 
We obtained the power spectrum of the phase images of the nuclei since these provide us with 
spatial scattering information at different length scales.  We calculated the point spread function 
using a 40X SLIM image and normalized the spatial scattering image of the nuclei.  We also did 
additional normalization to account for differences in amount of nuclei in each sample by 
normalization with a 1-D area obtained from the power spectrum images.   
We see multiple peaks in the low frequency (high length scale) region that corresponds to 
nucleus size and the peak is pushed to lower frequencies when multiple nuclei are in close 
proximity as seen in the Gleason score 4 adenocarcinoma patient.  In the higher frequency 
region, we obtain information regarding the nucleolar distribution and nuclear envelope 
continuity.  We notice that the peaks are arranged in the high-frequency region corresponding to 
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 Figure reprinted from Sridharan, S., Pham, H., Wickland, D., Tangella, K., Macias, V., Kajdacsy-Balla,A., 
Popescu, G., FTLS of nucleus during prostate cancer progression (manuscript in preparation)  
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6 radians/micron and 10 radians/micron in order of increasing severity with the only anomaly 
being the Gleason score 4 patient.   
 
 
 
Figure 16
15
: Top left: This shows the angular power spectrum for nuclei from Gleason 
score 4 (2+2) without any normalization, the inset shows the QPI image of the case.  Top 
right: In inset shows the point-spread function (PSF) and the curves show the measured 
and interpolated point spread function.  Bottom: Shows the normalized version of the 
power spectrum for the Gleason score 4 QPI image, where it has been normalized for both 
PSF and 1D area of the nuclei.   
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 Figure reprinted from Sridharan, S., Pham, H., Wickland, D., Tangella, K., Macias, V., Kajdacsy-Balla,A., 
Popescu, G., FTLS of nucleus during prostate cancer progression (manuscript in preparation)  
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Figure 17
16
: This shows the normalized power spectrum for the nuclei from various 
progression groups and in high frequency regions they align in order of increasing severity.  
5.4.4 Discussion 
Our results show that nuclear density is increased in low grade cancers whereas nuclear area is 
increased in higher grade cancers.  Previous studies have documented that nucleolar size is 
smaller in fast-growing tumors and is bigger in slow-growing prostate lesions [95].  Nucleolar 
count increase is also indicative of highly proliferative tumors since they are a reflection of 
ribosome production [96, 97].  Nuclear morphology is primarily determined by nuclear matrix 
proteins and lamins.  A study by Partin et. Al. showed a nuclear matrix protein PC1 was present 
in cancer nuclei but not in normal or BPH nuclei [98-101].  The nuclear lamina serves as 
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 Figure reprinted from Sridharan, S., Pham, H., Wickland, D., Tangella, K., Macias, V., Kajdacsy-Balla,A., 
Popescu, G., FTLS of nucleus during prostate cancer progression (manuscript in preparation)  
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attachment points for heterochromatin on the inner surface and also determines nuclear shape.  
Nuclear shape changes in papillary thyroid carcinoma with corresponding aggregation changes 
of heterochromatin has been documented before [93].  A change in nuclear matrix proteins 
would alter nuclear shape, whereas a change in nuclear lamin proteins would change nuclear 
density and nuclear shape.  It is not surprising that nuclear density would increase due to increase 
in the number of nucleoli since this is also a result of increased cellular proliferation and 
therefore DNA multiplication.  All of these explain the changes in nuclear density and area.     
The low frequency region in the nuclear spectroscopy reflects the nuclear size.  As expected 
from the nuclear analysis, the nuclear size is bigger in higher cancer grades.  The multiple peaks 
in this region, correspond to multiple nuclei adjacent to each other which is caused by increased 
proliferation seen in cancer.  In the higher frequency region (>5rad/micron), the spatial 
spectroscopy results organize the different grades of prostate disease in order of severity.  Since 
the information we obtain from phase images is related to dry protein distributions we think we 
measure information related to nuclear envelope discontinuities, nucleolar count and nuclear 
matrix protein distributions.  The spatial spectroscopy also summarizes the results from the 
nuclear density and area studies.  Study of spatial scattering from nuclei could prove to be a 
valuable pathological tool.  However, the data we studied here is limited and further studies need 
to be done to explore the clinical utility of this tool.  
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6. Summary & Future Work 
Prostate cancer has a very high incidence rate and the diagnostic process is expensive due to the 
use of expensive immunohistochemical markers.  Qualitative imaging methods such as GFM 
make the diagnosis of prostate cancer without the additional cost and delay associated with 
current clinical pathology practice.  Quantitative phase imaging methods such as SLIM 
combined with FTLS can detect very sensitive changes in tissue architecture without the use of 
stains.  We were able to show changes in both prostate nuclei and stroma in the intermediate risk 
categories where Gleason grading does not provide good prognostic measure.   
These methods show potential for a multitude of future applications: 
1. Gleason Grading: Studies have shown that urologic pathologists show a consensus of 
70% on Gleason grades whereas among general pathologists the consensus drops below 
50% for Gleason scores 5-7 [60, 61].  Since the Gleason grades determine the course of 
treatment, a more objective method is necessary to perform grading and remove inter-
observer variability.  QPI techniques can be used for this purpose. 
2. Prediction of prostate cancer recurrence: The current gold-standard to predict 
recurrence of prostate cancer is the CAPRA-S nomogram developed in University of 
California San Fransisco.  However, CAPRA-S discrimination is low in the D’Amico 
intermediate risk category.  Using QPI, we were able to detect changes in stroma among 
patients in this category, but we had no recurrence information associated with those 
patients.  We believe that QPI might have the sensitivity to improve the accuracy of 
recurrence prediction in this intermediate risk group. 
3. Field Effect Detection: There are instances where prostate cancer is not detected in a 
biopsy but is diagnosed in a repeat biopsy at an advanced stage.  This could be due to a 
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sampling error at the biopsy stage.  A sensitive tool that can detect pre-malignant changes 
and field effect associated with prostate cancer can solve this problem.  QPI shows 
promise in this area. 
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